Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

330 results about "Peripheral nervous system" patented technology

The peripheral nervous system (PNS) is one of two components that make up the nervous system of bilateral animals, with the other part being the central nervous system (CNS). The PNS consists of the nerves and ganglia outside the brain and spinal cord. The main function of the PNS is to connect the CNS to the limbs and organs, essentially serving as a relay between the brain and spinal cord and the rest of the body. Unlike the CNS, the PNS is not protected by the vertebral column and skull, or by the blood–brain barrier, which leaves it exposed to toxins and mechanical injuries.

Neural stimulation delivery device with independently moveable delivery structures

The present invention relates to a neural stimulation delivery device to deliver electrical and / or chemical stimulation to target sites in the central and peripheral nervous system. The device generally includes a tubular body defining a plurality of ports along the longitudinal axis thereof, a plurality of delivery structures insertable in the body, and a control mechanism in communication with the plurality of delivery structures to independently move each of the plurality of delivery structures through a respective one of the plurality of ports with respect to each other of the plurality of delivery structures. The ability of each delivery structure to be independently moveable through a respective port allows each delivery structure to be selectively advanced or retracted independent of the movement of another delivery structure.
Owner:THE CLEVELAND CLINIC FOUND

Universal closed-loop electrical stimulation system

A universal closed-loop functional electrical stimulation system comprising at least one electrode assembly adapted to deliver an electrical stimulation signal to the central nervous system, peripheral nervous system, or muscles of a user, a sensor system adapted to detect a mechanical response to a muscle stimulation signal of at least one muscle associated with a muscle group stimulated through the nervous system or proximate to the electrode assembly. An electrical stimulation device operably coupled to at least one electrode assembly and the sensor system, the electrical stimulation device including a control system to automatically receive feedback from at least one characteristic of the muscle from the detected muscle response and adjust at least one parameter of the muscle stimulation signal in real-time and in response thereto and a programmed microprocessor for controlling said electrical stimulation and receiving input from said sensor system.
Owner:HAMILTON MARILYN J +1

Surface stimulation for tremor control

Apparatus and methods for non-invasive electrical stimulation of the brain through skin surface stimulation of the peripheral nervous system as a treatment for movement disorders. Skin surface electrodes are positioned at predetermined peripheral surface stimulation sites on the skin surface using a variety of neural imaging techniques. A pulsatile electrical current is generated at the stimulation sites through a variety of standard electrical stimulation devices. Stimulation of the peripheral surface stimulation sites translates to electrical stimulation of a specific area of the brain.
Owner:MEAGAN MEDICAL

Neurogenesis by muscarinic receptor modulation

The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.
Owner:BRAINCELLS INC

4-Substituted piperidine derivatives

ActiveUS20050272751A1Promote neurite outgrowthPotential curative effectAntibacterial agentsBiocideDiseaseNervous system
Substituted piperidine compounds represented by the structure I are provided, wherein each of R1a, R1b, R1c, R1d, R1e, R1f, R1g, R1h, R2, R2A, R3, R4, A, X, a, x and n is as defined in the specification. Substituted piperidine compounds of structure I may permeate or penetrate across a nerve cell membrane into the interior of a nerve cell, may inhibit intracellular Rho kinase enzyme found in nerve cells in mammals, and may find utility in repair of damaged nerves in the central and peripheral nervous system of such mammals. These compounds may induce the regeneration or growth of neurites in mammalian nerve cells and may thereby induce regeneration of damaged or diseased nerve tissue. These compounds also find additional utility as antagonists of the enzyme Rho kinase in treatment of disease states in which Rho kinase is implicated. Pharmaceutical compositions containing these substituted piperidine compounds may be useful to promote neurite growth and in the treatment of diseases in which Rho kinase inhibition is indicated.
Owner:BIOAXONE BIOSCI

MODULATION OF NEUORGENESIS BY HDac INHIBITION

InactiveUS20070078083A1Maintain stabilize cognitive functionReducing a decline or decrease of cognitive functionBiocideSenses disorderNervous systemMedicine
The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on an HDac inhibitory agent alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.
Owner:BRAINCELLS INC

Direct molecular diagnosis of Friedreich ataxia

This invention relates generally to methods for the diagnosis and therapeutic treatment of Friedreich Ataxia. Friedreich ataxia (FRDA) is an autosomal recessive, degenerative disease that involves the central and peripheral nervous system and the heart. A gene, X25, was identified in the critical region for the FRDA locus on chromosome 9q13. The gene encodes a 210 amino acid protein, frataxin, that has homologues in distant species such as C. elegans and yeast. A few FRDA patients have been found to have point mutations in X25, but the vast majority are homozygous for a variable, unstable GAA trinucleotide expansion in the first X25 intron. Mature X25 mRNA was severely reduced in abundance in individuals with FRDA. Carriers and individuals at risk for developing FRDA can be ascertained by the methods of the present invention. Further, the methods of the present invention provide treatment to those individuals having FRDA.
Owner:BAYLOR COLLEGE OF MEDICINE +1

Complement inhibition for improved nerve regeneration

The present invention relates to methods and medicaments used for treating conditions that require axonal regeneration, e.g. in mammals affected by injury or disease of the central or peripheral nervous system. The medicaments used in these methods facilitate axonal regeneration by inhibition of the complement system. Conditions requiring axonal regeneration that may be treated in accordance with the invention include physical injuries as well as neurodegenerative disorders of the peripheral or central nervous system.
Owner:REGENESANCE

Implantable infrared nerve stimulation devices for peripheral and cranial nerve interfaces

Apparatus and method for making and using devices that generate optical signals, and optionally also electrical signals in combination with one or more such optical signals, to stimulate (i.e., trigger) and / or simulate a sensory-nerve signal in nerve and / or brain tissue of a living animal (e.g., a human), for example to treat nerve damage in the peripheral nervous system (PNS) or the central nervous system (CNS) and provide sensations to stimulate and / or simulate “sensory” signals in nerves and / or brain tissue of a living animal (e.g., a human) to treat other sensory deficiencies (e.g., touch, feel, balance, visual, taste, or olfactory) and provide sensations related to those sensory deficiencies, and / or to stimulate (i.e., trigger) and / or simulate a motor-nerve signal in nerve and / or brain tissue of a living animal (e.g., a human), for example to control a muscle or a robotic prosthesis.
Owner:LOCKHEED MARTIN CORP

Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death

The present invention relates to compositions and methods for the treatment and diagnosis of conditions, disorders, or diseases involving cell death. The invention encompasses protective nucleic acids which, when introduced into a cell predisposed to undergo cell death or in the process of undergoing cell death, prevent, delay, or rescue the cell from death relative to a corresponding cell into which no exogenous nucleic acids have been introduced. The invention encompasses nucleic acids of the protective sequence, host cell expression systems of the protective sequence, and hosts that have been transformed by these expression systems, including transgenic animals. The invention also encompasses novel protective sequence products, including proteins, polypeptides and peptides containing amino acid sequences of the proteins, fusion proteins of proteins, polypeptides and peptides, and antibodies directed against such gene products. The invention further relates to target sequences, including upstream and downstream regulatory sequences or complete gene sequences, antibodies, antisense molecules or sequences, ribozyme molecules, and other inhibitors or modulators directed against such protective sequences, protective sequence products, genes, gene products, and / or their regulatory elements involved in cell death. The present invention also relates to methods and compositions for the diagnosis and treatment of conditions, disorders, or diseases, involving cell death, including, but not limited to, treatment of the types of conditions, disorders, or diseases, which can be prevented, delayed or rescued from cell death and include, but are not limited to, those associated with the central nervous system, including neurological and psychiatric conditions, disorders, or diseases, and those of the peripheral nervous system. Further, the invention relates to methods of using the protective sequence, protective sequence products, and / or their regulatory elements for the identification of compounds that modulate the expression of the protective sequence and / or the activity of the protective sequence product. Such compounds can be useful as therapeutic agents in the treatment of various conditions, disorders, or diseases involving cell death.
Owner:COGENT NEUROSCI

Intravascular system and method for blood pressure control

An intravascular lead is used to deliver energy for stimulating nervous system targets using energy delivery elements (e.g. electrodes) that are in direct contact with the nervous system targets. The lead may be positioned within the internal jugular vein and the nervous system targets may include the carotid artery / carotid sinus bulb and / or associated baroreceptor afferents, and / or surrounding nervous system targets in the region of the internal jugular vein, such as the carotid sinus nerve and / or associated nerve branches and / or the vagus nerve and / or associated nerve branches. Stimulation energy travels along a conductive bridge that extends from the intravascular lead to the nervous system target, or is relayed from the intravascular lead to another device disposed within or surrounding the target structure.
Owner:INTERVENTIONAL AUTONOMICS

Sodium channel inhibitors

Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides substituted sulfonamides, compositions comprising these compounds, as well as methods of using these compounds or compositions in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrence of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a voltage-gated sodium channel.
Owner:ICAGEN INC

Compositions and methods for the treatment of disorders of the central and peripheral nervous systems

InactiveUS20060025387A1Suppressing neuronal excitabilityFunction increaseBiocideSalicyclic acid active ingredientsDiseaseNervous system
The present invention relates to methods and compositions for treating disorders of the central and / or peripheral nervous system by administering agents that are effective in reducing the effective amount, inactivating, and / or inhibiting the activity of a Na+—K+—2CT (NKCC) cotransporter. In certain embodiments, the Na+—K+—2Cl− co-transporter is NKCC1.
Owner:NEUROTHERAPEUTICS PHARMA

Production and Purification of Recombinant Arylsulftase

ActiveUS20080003211A1Facilitates tight controlHigh and uniform qualityNervous disorderBacteriaNervous systemPurification methods
The present invention pertains to a process for production of recombinant arylsulfatase A in a cell culture system, the process comprising culturing a mammalian cell capable of producing rASA in liquid medium in a system comprising one or more bio-reactors; and concentrating, purifying and formulating the rASA by a purification process comprising one or more steps of chromatography. Other aspects of the invention provides a pharmaceutical composition comprising rASA, which is efficiently endocytosed via the mannose-6-phosphate receptor pathway in vivo as well as a rhASA a medicament and use of a rhASA for the manufacture of a medicament for reducing the galactosyl sulphatide levels within target cells in the peripheral nervous system and / or within the central nervous system in a subject. A final aspect of the invention provides a method of treating a subject in need thereof, said method comprising administering to said subject a pharmaceutical composition comprising a rhASA and thereby obtaining a reduction in the galactosyl sulphatide levels in target cells within said subject.
Owner:TAKEDA PHARMA CO LTD

Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death

The present invention relates to compositions and methods for the treatment and diagnosis of conditions, disorders, or diseases involving cell death. The invention encompasses protective nucleic acids which, when introduced into a cell predisposed to undergo cell death or in the process of undergoing cell death, prevent, delay, or rescue the cell from death relative to a corresponding cell into which no exogenous nucleic acids have been introduced. The invention encompasses nucleic acids of the protective sequence, host cell expression systems of the protective sequence, and hosts that have been transformed by these expression systems, including transgenic animals. The invention also encompasses novel protective sequence products, including proteins, polypeptides and peptides containing amino acid sequences of the proteins, fusion proteins of proteins, polypeptides and peptides, and antibodies directed against such gene products. The invention further relates to target sequences, including upstream and downstream regulatory sequences or complete gene sequences, antibodies, antisense molecules or sequences, ribozyme molecules, and other inhibitors or modulators directed against such protective sequences, protective sequence products, genes, gene products, and / or their regulatory elements involved in cell death. The present invention also relates to methods and compositions for the diagnosis and treatment of conditions, disorders, or diseases, involving cell death, including, but not limited to, treatment of the types of conditions, disorders, or diseases, which can be prevented, delayed or rescued from cell death and include, but are not limited to, those associated with the central nervous system, including neurological and psychiatric conditions, disorders, or diseases, and those of the peripheral nervous system. Further, the invention relates to methods of using the protective sequence, protective sequence products, and / or their regulatory elements for the identification of compounds that modulate the expression of the protective sequence and / or the activity of the protective sequence product. Such compounds can be useful as therapeutic agents in the treatment of various conditions, disorders, or diseases involving cell death.
Owner:COGENT NEUROSCI

Apparatus and method for performing nerve conduction studies with multiple neuromuscular electrodes

InactiveUS20060020291A1Rapid and efficient assessmentElectrotherapySensorsNervous systemMedicine
There is provided an apparatus for assessment of peripheral nervous system function comprising: a stimulation and data acquisition unit; at least two neuromuscular electrodes; and an adaptor unit for connecting the at least two neuromuscular electrodes with the stimulation and data acquisition unit, such that the stimulation and data acquisition unit can independently communicate with each of the neuromuscular electrodes.
Owner:NEUROMETRIX INC

Neurogenesis by modulating angiotensin

InactiveUS20080167291A1High activityIncrease neurogenesisBiocideNervous disorderDiseaseNervous system
The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The invention includes compositions and methods based on modulation angiotensin activity to stimulate or activate the formation of new nerve cells.
Owner:BRAINCELLS INC

Nerve-penetrating apparatus and method for optical and/or electrical nerve stimulation of peripheral nerves

Apparatus and method for making and using devices that generate optical signals, and optionally also electrical signals in combination with one or more such optical signals, to stimulate (i.e., trigger) and / or simulate a sensory-nerve signal in nerve and / or brain tissue of a living animal (e.g., a human), for example to treat nerve damage in the peripheral nervous system (PNS) or the central nervous system (CNS) and provide sensations to stimulate and / or simulate “sensory” signals in nerves and / or brain tissue of a living animal (e.g., a human) to treat other sensory deficiencies (e.g., touch, feel, balance, visual, taste, or olfactory) and provide sensations related to those sensory deficiencies, and / or to stimulate (i.e., trigger) and / or simulate a motor-nerve signal in nerve and / or brain tissue of a living animal (e.g., a human), for example to control a muscle or a robotic prosthesis.
Owner:NUROTONE MEDICAL LTD

Self-Anchoring MEMS Intrafascicular Neural Electrode

The present invention provides a self anchoring electrode for recording, measuring and / or stimulating nerve activity in nerves and / or nerve fascicles of the peripheral nervous system, and methods for using such a self anchoring electrode.
Owner:ARIZONA STATE UNIVERSITY

Preventing and/or treating cardiovascular disease and/or associated heart failure

Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) toxic, drug-induced, and metabolic (including hypertensive and / or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the heart, and the central and peripheral nervous systems, (iv) plaque rupture of atheromatous lesions of major blood vessels such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the fermoral arteries and the popliteal arteries, (v) diabetes or the complications of diabetes.
Owner:PHILERA NEW ZEALAND +1

Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators

ActiveUS20050250833A1Effective activityBiocideSenses disorderN-phenylanthranilic acidDisease
Compounds, compositions and methods are provided which are useful in the treatment of conditions such as central or peripheral nervous system disorders through the modulation of potassium ion flux through voltage-dependent potassium channels and / or depressing cortical and / or peripheral neuron activity are disclosed. Novel derivatives of N-phenylanthranilic acid are also disclosed.
Owner:RAMOT AT TEL AVIV UNIV LTD

Agmatine, and polyaminoguanidine-bound heterocyclic compounds for neurotrauma and neurodegenerative diseases

The invention relates to the use of agmatine, in the treatment of acute neurotrauma (such as stroke) and degenerative disorders of the central and peripheral nervous system (such as dementia). The invention further provides novel compounds of general formula I (which are quinuclidine derivatives), formula II (which are norbornane derivatives), formula III (which are adamantane derivatives), and formula IV (which are phenothiazine derivatives): wherein R1, R2 and R3 are each independently hydrogen, hydroxy, substituted or unsubstituted C1-4 alkyl, substituted or unsubstituted C1-4 alkoxy, halogeno, amino, phenyl, or R4NR5; R4 and R5 are each independently hydrogen, or (CH2)n-[NH(CH2)x]y-NHR6, or (CH2)n-[NH(CH2)x]y-NH-NHR6, or (CH2)n-[NH(CH2)x]y-(NR7=)CNHR6, or (CH2)n-[NH(CH2)x]y-NH(NR7=)CNHR6 wherein n is from 0-5, y is from 0-5 and each x is independently from 1-5; R6, and R7 are each independently hydrogen, hydroxy, substituted or unsubstituted C1-4 alkyl, substituted or unsubstituted C1-4 alkoxy, or halogeno; and pharmaceutically acceptable salts and optically active isomers thereof.
Owner:GILAD GAD M +1

Antagonists of a non-selective cation channel in neural cells

InactiveUS20100092469A1Reduce mortalityReduces stroke sizeBiocideNervous disorderDiseaseNervous system
The present invention is directed to a combination of therapeutic compounds and treatment methods and kits using the combination. In particular, one of the combination affects the NCca-ATP channel of neural tissue, including neurons, glia and blood vessels within the nervous system. Exemplary SUR1 and / or TRPM4 antagonists that inhibit the NCca-ATP channel may be employed in the combination. The combination therapy also employs one or more of a non-selective cation channel blocker and / or an antagonist of VEFG, NOS, MMP, or thrombin. Exemplary indications for the combination therapy includes the prevention, diminution, and / or treatment of injured or diseased neural tissue, including astrocytes, neurons and capillary endothelial cells, that is due to ischemia, tissue trauma, brain swelling and increased tissue pressure, or other forms of brain or spinal cord disease or injury, for example. In other embodiments, there are methods and compositions directed to antagonists of TRPM4, including at least for therapeutic treatment of traumatic brain injury, cerebral ischemia, central nervous system (CNS) damage, peripheral nervous system (PNS) damage, cerebral hypoxia, or edema, for example.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPT OF VETERANS AFFAIRS

Polycaprolactone (PCL) static spinning nerve conduit and preparation and application thereof

The invention relates to a polycaprolactone (PCL) static spinning nerve conduit and preparation and application thereof. The polycaprolactone static spinning nerve conduit comprises an inner layer and an outer layer, wherein the inner layer is a reticular conduit made of high molecular degradable fibers, and the outer layer is a three-dimensional reticular structure which has high specific surface area and high porosity and is made of PCL sub-micron fibers jetted by adopting a static spinning method. The preparation of the verve conduit comprises the following steps: (1) weaving the high molecular degradable fibers and sleeving the high molecular degradable fibers into a static spinning device; (2) dissolving the PCL into a trichloromethane / methanol solution, and stirring the mixture; (3) performing static spinning of the PCL / trichloromethane / methanol solution; and (4) after the static spinning, taking off the nerve conduit, and packaging and sterilizing the nerve conduit. The nerve conduit is also a tissue engineering bracket for nerve reconstruction while the conduit wall plays a role in guiding and conveying nutrients; and the preparation method has the advantages of simple operation, low cost, no pollution to the environment, and high economic benefit, and is applied to restoring the peripheral nervous system.
Owner:DONGHUA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products